Huntington's disease (HD) is a deadly neurodegenerative disease with abnormal expansion of CAG repeats in the huntingtin gene. Mutant Huntingtin protein (mHTT) forms abnormal aggregates and intranuclear inclusions in specific neurons, resulting in cell death. Here, we tested the ability of a natural heat-shock protein 90 inhibitor, Gedunin, to degrade transfected mHTT in Neuro-2a cells and endogenous mHTT aggregates and intranuclear inclusions in both fibroblasts from HD patients and neurons derived from induced pluripotent stem cells from patients. Our data showed that Gedunin treatment degraded transfected mHTT in Neuro-2a cells, endogenous mHTT aggregates and intranuclear inclusions in fibroblasts from HD patients, and in neurons derived from induced pluripotent stem cells from patients in a dose- and time-dependent manner, and its activity depended on the proteasomal pathway rather than the autophagy route. These findings also showed that although Gedunin degraded abnormal mHTT aggregates and intranuclear inclusions in cells from HD patient, it did not affect normal cells, thus providing a new perspective for using Gedunin to treat HD.
Keywords: Degradation; Gedunin; Huntington’s disease; Mutant Huntingtin protein.
Conflict of interest statement
All authors claim that there are no conflicts of interest.
Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.Exp Neurol. 2018 Jan;299(Pt A):137-147. doi: 10.1016/j.expneurol.2017.10.019. Epub 2017 Oct 19. Exp Neurol. 2018. PMID: 29056363
Genistein induces degradation of mutant huntingtin in fibroblasts from Huntington's disease patients.Metab Brain Dis. 2019 Jun;34(3):715-720. doi: 10.1007/s11011-019-00405-4. Epub 2019 Mar 9. Metab Brain Dis. 2019. PMID: 30850940 Free PMC article.
A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration.FASEB J. 2013 May;27(5):1820-9. doi: 10.1096/fj.12-219220. Epub 2013 Jan 16. FASEB J. 2013. PMID: 23325320
Prion-like mechanisms in neurodegenerative disease: Implications for Huntington's disease therapy.Stem Cells Transl Med. 2020 Jan 30. doi: 10.1002/sctm.19-0248. Online ahead of print. Stem Cells Transl Med. 2020. PMID: 31997581 Review.
Mitochondrial dynamics and quality control in Huntington's disease.Neurobiol Dis. 2016 Jun;90:51-7. doi: 10.1016/j.nbd.2015.09.008. Epub 2015 Sep 24. Neurobiol Dis. 2016. PMID: 26388396 Review.